Sight Sciences (SGHT) Stock Overview
An ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SGHT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sight Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.05 |
| 52 Week High | US$9.21 |
| 52 Week Low | US$2.03 |
| Beta | 2.41 |
| 1 Month Change | 20.83% |
| 3 Month Change | 163.85% |
| 1 Year Change | 154.93% |
| 3 Year Change | -23.63% |
| 5 Year Change | n/a |
| Change since IPO | -72.99% |
Recent News & Updates
Recent updates
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Nov 13
Market Participants Recognise Sight Sciences, Inc.'s (NASDAQ:SGHT) Revenues Pushing Shares 37% Higher
Oct 18Sight Sciences Trying To Thread An Increasingly Narrow Needle
Aug 28Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet?
Aug 09Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
May 14
OMNIEdge And TearCare Will Transform MIGS Treatments
Strategic initiatives, such as the OMNIEdge launch and positive reimbursement for TearCare, aim to capture market share and improve revenue and margins.Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 30Is Sight Sciences (NASDAQ:SGHT) Using Debt Sensibly?
Jan 17Sight Sciences, Inc. (NASDAQ:SGHT) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
Nov 13Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge
Aug 15Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?
Jul 12Shareholder Returns
| SGHT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 11.0% | 0.9% | 3.1% |
| 1Y | 154.9% | 3.6% | 14.6% |
Return vs Industry: SGHT exceeded the US Medical Equipment industry which returned 3.4% over the past year.
Return vs Market: SGHT exceeded the US Market which returned 14.2% over the past year.
Price Volatility
| SGHT volatility | |
|---|---|
| SGHT Average Weekly Movement | 13.9% |
| Medical Equipment Industry Average Movement | 8.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SGHT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SGHT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 216 | Paul Badawi | www.sightsciences.com |
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Sight Sciences, Inc. Fundamentals Summary
| SGHT fundamental statistics | |
|---|---|
| Market cap | US$478.49m |
| Earnings (TTM) | -US$46.11m |
| Revenue (TTM) | US$76.05m |
Is SGHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGHT income statement (TTM) | |
|---|---|
| Revenue | US$76.05m |
| Cost of Revenue | US$10.61m |
| Gross Profit | US$65.44m |
| Other Expenses | US$111.55m |
| Earnings | -US$46.11m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 86.05% |
| Net Profit Margin | -60.63% |
| Debt/Equity Ratio | 62.3% |
How did SGHT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 03:07 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sight Sciences, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |
| Frank Takkinen | Lake Street Capital Markets, LLC |